Daraxonrasib reportedly reaches FDA review in pretreated pancreatic cancer — an oral RAS(ON) multi-selective inhibitor at the filing stage

What happened

Per secondary press reporting on July 22–23, 2026 (Stock Titan and CancerNetwork, both via Google News RSS), the FDA has accepted Revolution Medicines' New Drug Application for daraxonrasib in previously treated metastatic pancreatic cancer. ^[1][2] Prognyx could not locate a Revolution Medicines press release, an FDA statement, or an SEC filing confirming the acceptance in the primary sources reviewed as of this briefing; the milestone currently rests on aggregated news headlines carried as Google News RSS redirect links that do not resolve to durable publisher URLs. Prognyx treats it as unconfirmed press reporting until a primary Revolution Medicines or FDA source lands.

One piece of the pathway is on the record. Revolution Medicines had stated its intent to submit the RASolute 302 NDA to the FDA under a Commissioner's National Priority Voucher. ^[4] Whether the agency actually assigned that pathway on acceptance — or Priority Review, or Real-Time Oncology Review — is not established in the reported sources, and no PDUFA target action date is disclosed.

Daraxonrasib (RMC-6236; ChEMBL CHEMBL6168538) is an oral RAS(ON) multi-selective inhibitor — designed to drug the active, GTP-bound ("ON") state of RAS across mutant variants rather than one allele at a time. ^[3][11]

The data behind the filing

The submission follows the pivotal RASolute 302 trial. On April 13, 2026, Revolution Medicines announced that RASolute 302 — a global Phase 3 study of daraxonrasib monotherapy in previously treated metastatic PDAC, enrolling across the U.S., EU and Japan — met all primary and key secondary endpoints, including progression-free survival and overall survival. ^[4][5] The topline is, so far, qualitative: the specific medians, hazard ratios, confidence intervals, patient numbers and RAS-mutation subgroup splits from RASolute 302 are not in the public record Prognyx reviewed, and the trial's ClinicalTrials.gov registration and current status could not be confirmed from the sources here.

What is public is the earlier monotherapy dataset that set the Phase 3 dose. At 300 mg once daily — the RASolute 302 dose — the July 23, 2024 cutoff showed median PFS of 8.8 months (95% CI 8.5–NE) in PDAC patients with a KRAS G12X mutation, with OS not estimable, and 8.5 months in patients with any RAS mutation. ^[3] Separately, the earlier EORTC-NCI-AACR dose-ranging dataset across a 160–300 mg range put median PFS at 8.5 months (95% CI 5.3–11.7) and median OS at 14.5 months (95% CI 8.8–NE) in KRAS G12X patients, with any-RAS patients at 7.6 months PFS and 14.5 months OS. ^[3] These are earlier monotherapy figures — not the RASolute 302 result — and should not be read as the pivotal numbers. Safety in those datasets was manageable: rash and GI toxicity dominated, mostly Grade 1–2, with no Grade 3+ treatment-related adverse event in more than 10% of patients and no discontinuations for TRAEs. ^[3]

Why it matters

The strategic point is coverage. Roughly 50% of PDAC patients present with a KRAS G12D mutation, per figures cited in a July 2026 preclinical EMBO Journal study — not a dedicated epidemiology source. ^[10] A G12D-selective or G12C-selective agent addresses one slice of that population; daraxonrasib's multi-selective RAS(ON) mechanism reaches the broader G12X / any-RAS population in a single oral drug. That is why the two details still missing from the reported filing — the precise RAS mutations covered and whether the label is confined to "previously treated" — will be the most consequential facts when the NDA specifics surface. Revolution Medicines has separately been planning first-line metastatic and adjuvant (resectable) PDAC registrational trials, so a pretreated indication would be the first of several intended lines. ^[5]

Who gained

Royalty Pharma. Under the June 2025 agreement, Royalty Pharma committed up to $2 billion to daraxonrasib — a synthetic royalty of up to $1.25 billion plus a senior secured loan of up to $750 million — funding $250 million upfront. ^[4] The April 13, 2026 positive readout triggered a further $250 million; another $250 million of synthetic royalty unlocks on FDA approval in metastatic PDAC, and the first $250 million loan tranche must be drawn following that approval. ^[4] Royalty Pharma earns tiered royalties of 4.55% on the first $2B of net sales, 2.50% on $2–4B and 1.00% on $4–8B, scaling up to 7.80% / 4.55% / 2.40% if the full remaining $750M synthetic royalty is drawn. ^[4] The structure is worth reading closely: the cash-flow trigger is approval, not acceptance — the reported NDA milestone moves nothing on the financing schedule until the FDA acts on the file.

Who is exposed

Anyone betting on single-allele RAS inhibition in PDAC now faces a multi-selective agent reportedly at the filing stage in the pretreated setting. Revolution Medicines itself runs two allele-selective RAS(ON) inhibitors — elironrasib (RMC-6291, G12C-selective) and zoldonrasib (RMC-9805, G12D-selective). ^[3] Prognyx reads that portfolio design as positioning daraxonrasib as the broad-RAS backbone and the selective agents as combination or later-line partners — an interpretation, not a company statement.

The scientific caveat sits in the same window. A July 2026 preclinical EMBO Journal study reports that CDK8 remodels the tumor microenvironment and drives resistance to both KRAS G12D inhibitors and daraxonrasib in PDAC models — an early, laboratory-stage flag that durability may hinge on combinations, not monotherapy. ^[10] Daraxonrasib in advanced RAS-mutated PDAC is also the subject of NEJM correspondence published July 1, 2026, whose content Prognyx did not review beyond its title and DOI. ^[9]

What to watch (with dates)

• PDUFA / target action date: not disclosed in the sources reviewed. This is the decisive unknown — the event that flips the Royalty Pharma milestones and, if positive, the label.
• Assigned review designation: Revolution Medicines had signaled intent to file under a Commissioner's National Priority Voucher; the pathway the FDA actually granted on acceptance is unconfirmed in the reported sources. ^[4]
• EMA accelerated (phased) review: opened around July 7, 2026 (EMA, corroborated by Reuters on 2026-07-07) — a parallel path in metastatic PDAC, not an approval. ^[7][8]
• Expanded access: the FDA issued a "safe to proceed" letter around May 1, 2026 permitting an expanded access treatment protocol for daraxonrasib in pancreatic cancer. ^[6]
• NSCLC: RASolve 301, a Phase 3 of daraxonrasib versus docetaxel in previously treated RAS-mutant NSCLC, was activating sites as of May 2025. ^[5]
• Earlier lines: first-line and adjuvant PDAC registrational trials were planned for 2H 2025; their current initiation status is not confirmed in the sources reviewed. ^[5]

The now-what

For a biotech operator with a RAS or PDAC program, three moves are on the table.

1. Re-test differentiation on mutation coverage and line of therapy. Daraxonrasib is filing broad-RAS in the pretreated setting; the open lanes are first-line, adjuvant, allele-specific niches, and combinations that answer the preclinical CDK8 / tumor-microenvironment resistance axis. ^[10]

2. Wait for the label before sizing the white space. The RAS mutations and population in the eventual indication define the addressable market; until the NDA specifics are public, this is unresolved and should not be modeled as pan-RAS by default.

3. Benchmark the financing. The Royalty Pharma structure — up to $2B tied to approval milestones and tiered to $8B of sales — is a live template for how a de-risked RAS asset gets funded without dilution, and a yardstick for any comparable deal. ^[4]

Verdict: Threat level is high for allele-specific PDAC programs, but contingent — the reported acceptance advances the file, not the approval. The window to act is the interval between now and an undisclosed PDUFA date, with the EMA accelerated review running in parallel; Prognyx will revise this read the moment a primary Revolution Medicines or FDA source confirms the acceptance and its terms.